Pharmacia Italia S.p.a.

Nerviano Medical Sciences S.r.l.

Pharmacia Corporation

Nerpharma S.r.l.

Attilio Tomasi

Mario Ungari

Stefania Magenes

Giuliano Ramella

Ilaria Candiani

Marco Pandolfi

Giovanni Ottaiano

Gianfranco Pallanza

Francesco Saverio Caldarelli

Francesco Corcella

The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.

Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide

Carmustine may be safely and efficiently produced by reacting 2-chloroethylamine hydrochloride and 1,1'-carbonyldiimidazole to afford 1,3-bis(2-chloroethyl)-1-urea, followed by nitrosation to give the final product.

Safe and efficient process for the preparation of carmustine

A process for producing crystalline form I of cabergoline, which process comprises crystallization of the desired form from a toluene/diethyl ether mixture comprising raw cabergoline, followed by recovery and drying of the resulting crystals. A new solvate form V of cabergoline, useful as an intermediate, is also provided.

Process for preparing crystalline Form I of cabergoline

Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from s solution of raw cabergoline in an organic solvent at low temperatures or submitting to a slurry procedure a mixture of cabergoline forms I and II in a solvent at a temperature below 30&deg; C.

Crystalline form II of cabergoline

Process for preparing crystalline form I of cabergoline

Crystalline form II of cabergoline, a pharmaceutical composition containing it and a process for its preparation are disclosed. The process may comprise crystallization from a solution of raw cabergoline in an organic solvent at low temperatures or submitting to a slurry procedure a mixture of cabergoline Forms I and II in a solvent at a temperature below about 30&deg; C.

Crystalline form II cabergoline

Growing community of inventors

Milan, Italy

Attilio Tomasi